Correction to “Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSpondyloarthritis Studies and Treatments · Psoriasis: Treatment and Pathogenesis · Rheumatoid Arthritis Research and Therapies
McInnes, IB , Mease, PJ , Tanaka, Y et al. Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies. ACROpen Rheumatol. 2024;6(11):720–731. doi: 10.1002/acr2.11727 PMC1155799039077886
In this article, the Disease Activity Index for Psoriatic Arthritis (DAPSA) disease states were calculated incorrectly across all treatment arms and timepoints, resulting in patients being wrongly allocated to a worse DAPSA disease state.
This error impacted three rows in Table 2. The corrected rows from Table 2 are provided below.
Excerpt from Table 2:BE OPTIMAL (bDMARD‐naïve)BE COMPLETE (TNFi‐IR)Placebo (n = 281)BKZ 160 mg Q4W (n = 431)Placebo (n = 133)BKZ 160 mg Q4W (n = 267)+MTX, n = 163−MTX, n = 118+MTX, n = 252−MTX, n = 179+MTX, n = 51−MTX, n = 82+MTX, n = 119−MTX, n = 148DAPSA (WCI)LDA and REM,^a^ n (%)113 (69.3)72 (61.0)170 (67.5)109 (60.9)25 (49.0)41 (50.0)69 (58.0)88 (59.5)REM, n (%)42 (25.8)31 (26.3)91 (36.1)67 (37.4)12 (23.5)13 (15.9)42 (35.3)44 (29.7)95% CI18.2 to 35.117.5 to 37.429.0 to 43.929.0 to 46.712.1 to 40.78.3 to 28.325.3 to 46.721.3 to 39.8Randomized set. bDMARD, biologic disease‐modifying antirheumatic drug; BKZ, bimekizumab; CI, confidence interval; DAPSA, Disease Activity Index for Psoriatic Arthritis; LDA, low disease activity; +MTX, with methotrexate; −MTX, without methotrexate; Q4W, every four weeks; REM, remission; TNFi‐IR, prior inadequate response or intolerance to tumor necrosis factor inhibitors; WCI, worst‐category imputation. ^a^ Calculated by hand; 95% CIs are not available.